Neuropsych biotech LB Pharmaceuticals (LBRX) filed for a $100 million IPO on Friday, marking the first major new filing from a drug developer since January.
Backed by a suite of VCs, LB Pharmaceuticals is initially developing its lead candidate, oral small molecule LB-102, for acute schizophrenia, though it also plans to target other indications, including bipolar depression. The company announced positive Phase 2 data in early 2025 and plans to initiate a Phase 3 trial of LB-102 in acute schizophrenia in the 1Q26, with topline data expected in the 2H27. Positive data could mean a meeting with the FDA to discuss a potential NDA submission by the 1Q28.
With an anticipated listing timeline of September, LB Pharmaceuticals is poised to be...
To read the rest of the article, sign up for a free trial of IPO Pro, the platform that gives you all of the IPO information you need, all in one place.
